1. <tt id="ghyqw"></tt>
    <xmp id="ghyqw"></xmp>
    <i id="ghyqw"><track id="ghyqw"></track></i>

  2. <blockquote id="ghyqw"></blockquote>

    在研產品

    CAR-T

    CAR-T,全稱是Chimeric Antigen Receptor T-Cell Immunotherapy,指嵌合抗原受體T細胞免疫療法。嵌合抗原受體(CAR)是CAR-T細胞的核心部件,賦予T細胞以HLA非依賴的方式識別腫瘤抗原和殺傷/死腫瘤細胞的能力,這使得經過CAR改造的T細胞相較于天然T細胞表面受體TCR(T cell receptor)能夠識別更廣泛的目標。

    相較于其他療法,CAR-T細胞療法具有治療更精準、多靶向更精準、殺瘤范圍更廣、殺瘤效果更持久等優勢,在血液腫瘤治療方面,已起到了很好的療效。

    CAR-T產品管線

    CYL-219

    Area of Research: ALL,MM

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    hCD19

    Area of Research: ALL,CLL,NHL,DLBCL,MCL

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CD19+BCMA

    Area of Research: MM

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CD20

    Area of Research: Heme Malignancies

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CD22

    Area of Research: ALL,NHL,DLBCL

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CD19-CD22

    Area of Research: ALL

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CYL-269

    Area of Research: MM

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CD30

    Area of Research: Heme Malignancies

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CD33

    Area of Research: Heme Malignancies

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CD38

    Area of Research: MM

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CYL-307

    Area of Research: MM

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    NY-ESO-1

    Area of Research: MM,HCC,TCR-T

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    ROR1

    Area of Research: CLL,MCL

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    GPC-3

    Area of Research: HCC

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    EGFR vⅢ

    Area of Research: BC,NSCLC

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CAR-NK

    NK細胞是一類對腫瘤細胞具有強力殺傷作用且MHC非依賴的淋巴細胞,其對腫瘤細胞的識別主要依賴于其表面活化性受體和抑制性受體的相互交叉調控。NK細胞因其特殊的識別靶細胞的機制、短暫的生理周期、廣泛的腫瘤殺傷能力等優勢,被視為同樣有潛力通過CAR修飾增強其抗腫瘤能力的效應細胞。當識別腫瘤細胞之后,NK細胞通過釋放殺傷介質穿孔素和顆粒酶使靶細胞凋亡、表達膜TNF家族分子誘導靶細胞凋亡和抗體依賴的細胞毒作用等多種途徑殺傷腫瘤細胞。

    CAR-NK主要的優勢是不需要激活NK細胞內源性的細胞毒性受體,選擇性地識別腫瘤相關抗原,有道抗原特異性的靶細胞裂解,對實體腫瘤治療具有明顯優勢。

    CAR-NK產品管線

    CAR-NK, GPC-3

    Area of Research: HCC

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CAR-NK, EGFR

    Area of Research: BC, NSCLC

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CAR-NK, CD19

    Area of Research: ALL,CLL,NHL,DLBCL,MCL

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CAR-NK, BCMA

    Area of Research: MM

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    CAR-NK, CYL-307

    Area of Research: MM

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    iPSC

    iPSC產品管線

    iPSC, Cadiocyte

    Area of Research: Myocardial infarction

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    iPSC來源的NK

    Area of Research: 美容、保健、醫療

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ

    iPSC來源的T細胞

    Area of Research: 通用型CAR-T

    Drug Discovery
    Pre-IND
    PhaseⅠ
    PhaseⅡ
    PhaseⅢ
    在研產品
    聯系我們

    027-87002135

    2812304655@qq.com

    99在线视频播放器 在线看香蕉吚人AV在线 欧美老司机 亚洲欧美人成网站在线观看
    夫目前侵犯中文字幕 国模娜娜超大尺度具自慰 手机看片久久国产免费 免费中文字幕视频 欧美一级片在线